The Business Research Company’s Cell
Based Assays Market covers market characteristics, size and growth,
segmentation, regional and country breakdowns, competitive landscape, market
shares, trends and strategies for this market.
The cell based assays market
consists of sales of cell based assays. Cell-based assays are analytical tools
that are designed to study a mechanism or process of cellular function.
Companies developing cell based assays provide consumables such as reagents,
assays kits and microplates as well as instruments, services and software. This
report includes sales of reagents, cell lines, microplates, microplate, assay
kits, probes and labels, and others.
Major players in the market are Thermo Fisher, Danaher , Becton,
Dickinson and Company, GE Healthcare, Merck
Research with cell based arrays
is increasing with evolution and there is a definite need to move to more
predictive cellular models for drug discovery in order to control the
last-stage drug failures. The pharmaceutical industries’ need to efficiently
commercialize drugs in order to overcome expensive failures in the last stages
is a driving force in cell-based assay innovation. Failure of investigational
new drug (IND) Phase III clinical trials results in a loss of several hundred
million dollars to that company. For instance, according to report by Sigma,
the return on investment for pharmaceutical companies could drop to 5%
considering the current level of late-stage failures, and is an unacceptable
level for most companies. Major improvements to high-content systems and data
analysis from the cell based assays enable scientists to extract a more information
about the cellular response and help take informed decisions during drug
discovery, and further driving the market for cell based arrays.
High cost of instruments is the
major factor restraining the global cell based assays market. High price of the
instrumentation will reduce the return on investments (ROI) owing to low
adaptation. For example, Biotek developed HCA (high content analysis)
instruments and are expensive and reserved for industrial end-users or core
labs which have sufficient capital budgets. This restricts the low budgeted
end-users to use cell based assays to its full potential, thereby hampering the
growth of the market.
Researchers are inclining towards
early phase predictive toxicity testing that prevent late-stage drug failures.
Predictive cell toxicity assays are being scaled up to increase screening of
compounds in the early phases of drug development, reducing the cost of
failure. For instance, Creative Bioarray, a biotech company provides a range of
in vitro toxicity services to check drug-induced toxicities that save time and
cost by reducing the chance of failure in earlier stage. These advances will
make clinical testing easy and reduce the cost of operation.
View complete Report: https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report
About Us:
The Business Research Company is a Business Intelligence
Company which excels in company, market and consumer research. It has offices
in the UK, the US and India and a network of trained researchers in 15
countries globally.
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
View Our Latest Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
Comments
Post a Comment